Aeglea BioTherapeutics logo
Aeglea BioTherapeutics AGLE
$ 12.01 0.0%

Quarterly report 2025-Q2
added 08-05-2025

report update icon

Aeglea BioTherapeutics Financial Statements 2011-2025 | AGLE

Annual Financial Statements Aeglea BioTherapeutics

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

724 M 433 M 1.35 M 12.5 M 420 M 226 M 187 M 104 M 39.3 M - - - - -

Shares

60.3 M 36.1 M 3.37 M 2.63 M 53.4 M 31.9 M 20.8 M 15.1 M 9.79 M - - - - -

Historical Prices

12 12 0.4 4.75 7.87 7.64 7.49 5.41 4.35 - - - - -

Net Income

-208 M -339 M -83.8 M -65.8 M -80.9 M -78.3 M -44.3 M -27.2 M -21.7 M -11.3 M -10.3 M - - -

Revenue

- 886 K 2.33 M 18.7 M 21.8 K - 3.89 M 5.2 M 4.63 M 6.08 M - - - -

Operating Income

-209 M -242 M -84.8 M -65.6 M -81.5 M -80.3 M -45.5 M -27.7 M -21.9 M -11.3 M -8.9 M - - -

Interest Expense

-20.7 M -19.1 M -7 K -122 K -5 K -63 K -57 K -42 K -36 K -2 K - - - -

EBITDA

- -242 M -83.2 M -64.1 M -80.5 M -79.9 M -45.2 M -27.4 M -21.8 M -11.2 M -7.44 M - - -

Operating Expenses

209 M 243 M 87.1 M 84.4 M 81.5 M 80.3 M 49.4 M 32.9 M 26.5 M 17.4 M - - - -

General and Administrative Expenses

45.8 M 39.9 M 28.5 M 27.3 M 21.8 M 15.7 M 12.6 M 10.1 M 8.39 M 5.95 M 2.07 M - - -

All numbers in USD currency

Quarterly Income Statement Aeglea BioTherapeutics

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

60.4 M 60.3 M 60.3 M 50.9 M 45.3 M 36.5 M 36.1 M 4.29 M 3.82 M 3.77 M 2.61 M 3.77 M 82.2 M 66 M 49.4 M 65.8 M 65.6 M 65.6 M 48 M 62.2 M 52.9 M 33.1 M 29.1 M 32.9 M 32.8 M 29 M 24.1 M 22 M 20.6 M 16.7 M 16.7 M 16.4 M 14.1 M 13.4 M 13.4 M 13.3 M 11.8 M 641 K 757 K 613 K 586 K 573 K - - - - - - - - - - - - - - - -

Net Income

-36.7 M -44.8 M - -69 M -38.8 M -43.9 M - -40.1 M -217 M -18.4 M - -18.2 M -22.3 M -24.4 M - -20.3 M -6.83 M -18.2 M -22.7 M -18 M -21.4 M -18.7 M -21.5 M -21.6 M -18 M -17.2 M -14.9 M -11.9 M -9.41 M -8.12 M -6.48 M -7.87 M -6.63 M -6.25 M -5.48 M -6.24 M -5.43 M -4.55 M -3.99 M -3.41 M -1.43 M -2.47 M - - - - - - - - - - - - - - - -

Revenue

- - - - - - - - 688 K 198 K - 174 K 625 K 1.36 M - 1.4 M 13.7 M - - - - - - - - - - - 2.38 M 1.51 M 1.48 M 1.26 M 1.48 M 982 K - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-41.9 M -53.6 M - -55.4 M -44.1 M -47.8 M - -18.3 M -159 M -18.8 M - -18.8 M -22.4 M -24.4 M - -20.3 M -6.7 M -18.2 M -22.8 M -18.1 M -21.6 M -19 M -21.9 M -22.1 M -18.6 M -17.7 M -15.3 M -12.2 M -9.67 M -8.24 M -6.63 M -8 M -6.72 M -6.33 M -5.54 M -6.3 M -5.5 M -4.57 M -4 M -3.42 M -1.43 M -2.47 M - - - - - - - - - - - - - - - -

Interest Expense

-656 K 2.29 M - -18.8 M -610 K -483 K - 2.34 M -8 K -72 K - 24 K 5 K -30 K - -24 K -52 K -31 K - 2 K -19 K -6 K - -12 K -16 K -17 K - -13 K -7 K -17 K - -12 K -12 K -11 K - -9 K -9 K -6 K - -1 K - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - - - - - -18.4 M - -17.6 M -22.4 M -24 M - -19.1 M -6.7 M -17.9 M -22.8 M -17.5 M -21.2 M -18.9 M -21.9 M -21.8 M -18.4 M -17.6 M -15.3 M -12 M -9.52 M -8.18 M -6.63 M -7.82 M -6.61 M -6.28 M -5.54 M -6.2 M -5.43 M -4.54 M -4 M -3.36 M -1.4 M -2.45 M - - - - - - - - - - - - - - - -

Operating Expenses

41.9 M 53.6 M - 55.4 M 44.1 M 47.8 M - 18.3 M 160 M 19 M - 18.9 M 23 M 25.8 M - 21.7 M 20.4 M 18.2 M - 18.1 M 21.6 M 19 M - 22.1 M 18.6 M 17.7 M - 12.2 M 12 M 9.76 M - 9.26 M 8.2 M 7.31 M - 7.45 M 6.87 M 5.43 M - 4.49 M 4.86 M 2.47 M - - - - - - - - - - - - - - - -

General and Administrative Expenses

11.8 M 11.9 M - 10.6 M 11.5 M 12.8 M - 8.58 M 12.1 M 5.23 M - 6.95 M 7.68 M 8.82 M - 6.84 M 6.82 M 6.35 M - 5.67 M 4.69 M 4.46 M - 4.31 M 3.82 M 3.27 M - 3.31 M 2.93 M 2.88 M - 3.02 M 2.36 M 2.36 M - 2.06 M 2.45 M 1.83 M - 1.36 M 2.12 M 847 K - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Aeglea BioTherapeutics AGLE
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Aeglea BioTherapeutics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Cellectis S.A. Cellectis S.A.
CLLS
$ 4.3 12.57 % $ 116 M franceFrance
Graybug Vision Graybug Vision
GRAY
$ 0.44 -11.23 % $ 9.65 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
$ 11.3 -10.17 % $ 12.2 K -
Galera Therapeutics Galera Therapeutics
GRTX
$ 0.14 -32.59 % $ 7.61 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 2.52 -1.18 % $ 6.35 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
$ 4.37 -1.58 % $ 28.1 M chinaChina
Caladrius Biosciences Caladrius Biosciences
CLBS
$ 0.43 -16.75 % $ 25.8 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
$ 0.27 -29.58 % $ 126 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
$ 184.71 0.49 % $ 251 B cayman-islandsCayman-islands
Midatech Pharma plc Midatech Pharma plc
MTP
$ 0.29 -18.52 % $ 27.3 M britainBritain
Aeterna Zentaris Aeterna Zentaris
AEZS
$ 5.72 5.93 % $ 314 M canadaCanada
ContraFect Corporation ContraFect Corporation
CFRX
$ 1.47 -5.16 % $ 5.39 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
$ 4.93 1.02 % $ 90.8 M britainBritain
Advaxis Advaxis
ADXS
$ 0.31 -9.65 % $ 45.9 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
$ 3.93 -5.76 % $ 99.8 M usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
$ 6.2 - $ 154 M usaUSA
Zymeworks Zymeworks
ZYME
$ 6.42 - $ 404 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
$ 10.5 - $ 231 M usaUSA
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
$ 9.5 - $ 1.7 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
$ 2.58 -4.8 % $ 255 M usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
$ 0.56 7.23 % $ 2.72 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
$ 0.5 - $ 7.46 M israelIsrael
Generation Bio Co. Generation Bio Co.
GBIO
$ 6.33 1.61 % $ 408 M usaUSA
Kiromic BioPharma Kiromic BioPharma
KRBP
$ 3.15 6.61 % $ 3.08 M usaUSA
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
$ 179.68 - $ 10.9 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
$ 44.15 -0.23 % $ 916 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
$ 0.32 - $ 23.9 M usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
$ 18.44 - $ 1.94 B canadaCanada
Kaleido Biosciences Kaleido Biosciences
KLDO
$ 0.29 -3.69 % $ 12.4 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
$ 2.19 - $ 105 M usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
$ 1.35 2.27 % $ 206 M usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 6.59 2.17 % $ 53.8 M usaUSA
Humanigen Humanigen
HGEN
$ 0.04 -81.12 % $ 4.28 M usaUSA
Aptinyx Aptinyx
APTX
$ 0.06 -39.0 % $ 4.57 M usaUSA
Tyme Technologies Tyme Technologies
TYME
$ 0.31 8.07 % $ 54 M usaUSA
Keros Therapeutics Keros Therapeutics
KROS
$ 15.96 1.98 % $ 598 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
$ 2.64 -0.75 % $ 18.7 M danmarkDanmark
Krystal Biotech Krystal Biotech
KRYS
$ 187.18 2.27 % $ 5.35 B usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
$ 56.29 -1.11 % $ 4.22 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
$ 0.39 - $ 26.5 M usaUSA
Celyad Oncology SA Celyad Oncology SA
CYAD
$ 0.47 - $ 12.5 M belgiumBelgium
Brickell Biotech Brickell Biotech
BBI
$ 2.11 -5.38 % $ 6.06 M usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
$ 0.05 -15.0 % $ 3.04 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
$ 0.06 -55.98 % $ 2.15 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
$ 8.37 - $ 401 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
$ 3.17 1.93 % $ 17.4 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
$ 0.37 -10.95 % $ 876 K usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
$ 20.01 - $ 958 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
$ 49.55 -6.81 % $ 3.04 B usaUSA
Sierra Oncology Sierra Oncology
SRRA
$ 54.89 -0.05 % $ 1.34 B canadaCanada